1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer

1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2018-10, Vol.29 (suppl_8)
Hauptverfasser: Colombo, N, Nicoletto, O, Benedetti Panici, P, Tognon, G, Lissoni, A A, Bologna, A, Tomao, F, Fossati, R, Tettamanzi, F, Rulli, E, Galli, F, Alvisi, M F, Torri, V, Biagioli, E
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue suppl_8
container_start_page
container_title Annals of oncology
container_volume 29
creator Colombo, N
Nicoletto, O
Benedetti Panici, P
Tognon, G
Lissoni, A A
Bologna, A
Tomao, F
Fossati, R
Tettamanzi, F
Rulli, E
Galli, F
Alvisi, M F
Torri, V
Biagioli, E
description
doi_str_mv 10.1093/annonc/mdy285.209
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdy285_209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy285.209</oup_id><sourcerecordid>10.1093/annonc/mdy285.209</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdy285_2093</originalsourceid><addsrcrecordid>eNqVkE1OwzAUhC0EEuHnAOzeAUjrJE1p2JUIRFdFqPvo1XaVB44d2U5LOCRnIlGR2CGxms03o9HH2E3CJwkvsikaY42YNrJPF_kk5cUJi5J8XsQLPktOWcSLNIvv8mx2zi68f-Ocz4u0iNhXwnm6oZeH5eu6LNf3sASHRtqGPpWEtkavYLUCHzrZg93BQal33UOLQlPAD6Vh70EoSUOLtrHV2KKjLRwo1CCsCWQ623nwolay0-ovnExQrqEQlAm_BTKAco9GjH80joMNOOXJBxw4ux8G0IAYCXfFznaovbr-yUt2-_S4KZ9j27VV66hB11cJr0Zn1dFZdXRWDc6yf-LfPc98NA</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Colombo, N ; Nicoletto, O ; Benedetti Panici, P ; Tognon, G ; Lissoni, A A ; Bologna, A ; Tomao, F ; Fossati, R ; Tettamanzi, F ; Rulli, E ; Galli, F ; Alvisi, M F ; Torri, V ; Biagioli, E</creator><creatorcontrib>Colombo, N ; Nicoletto, O ; Benedetti Panici, P ; Tognon, G ; Lissoni, A A ; Bologna, A ; Tomao, F ; Fossati, R ; Tettamanzi, F ; Rulli, E ; Galli, F ; Alvisi, M F ; Torri, V ; Biagioli, E</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy285.209</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2018-10, Vol.29 (suppl_8)</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Colombo, N</creatorcontrib><creatorcontrib>Nicoletto, O</creatorcontrib><creatorcontrib>Benedetti Panici, P</creatorcontrib><creatorcontrib>Tognon, G</creatorcontrib><creatorcontrib>Lissoni, A A</creatorcontrib><creatorcontrib>Bologna, A</creatorcontrib><creatorcontrib>Tomao, F</creatorcontrib><creatorcontrib>Fossati, R</creatorcontrib><creatorcontrib>Tettamanzi, F</creatorcontrib><creatorcontrib>Rulli, E</creatorcontrib><creatorcontrib>Galli, F</creatorcontrib><creatorcontrib>Alvisi, M F</creatorcontrib><creatorcontrib>Torri, V</creatorcontrib><creatorcontrib>Biagioli, E</creatorcontrib><title>1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkE1OwzAUhC0EEuHnAOzeAUjrJE1p2JUIRFdFqPvo1XaVB44d2U5LOCRnIlGR2CGxms03o9HH2E3CJwkvsikaY42YNrJPF_kk5cUJi5J8XsQLPktOWcSLNIvv8mx2zi68f-Ocz4u0iNhXwnm6oZeH5eu6LNf3sASHRtqGPpWEtkavYLUCHzrZg93BQal33UOLQlPAD6Vh70EoSUOLtrHV2KKjLRwo1CCsCWQ623nwolay0-ovnExQrqEQlAm_BTKAco9GjH80joMNOOXJBxw4ux8G0IAYCXfFznaovbr-yUt2-_S4KZ9j27VV66hB11cJr0Zn1dFZdXRWDc6yf-LfPc98NA</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Colombo, N</creator><creator>Nicoletto, O</creator><creator>Benedetti Panici, P</creator><creator>Tognon, G</creator><creator>Lissoni, A A</creator><creator>Bologna, A</creator><creator>Tomao, F</creator><creator>Fossati, R</creator><creator>Tettamanzi, F</creator><creator>Rulli, E</creator><creator>Galli, F</creator><creator>Alvisi, M F</creator><creator>Torri, V</creator><creator>Biagioli, E</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20181001</creationdate><title>1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer</title><author>Colombo, N ; Nicoletto, O ; Benedetti Panici, P ; Tognon, G ; Lissoni, A A ; Bologna, A ; Tomao, F ; Fossati, R ; Tettamanzi, F ; Rulli, E ; Galli, F ; Alvisi, M F ; Torri, V ; Biagioli, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdy285_2093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colombo, N</creatorcontrib><creatorcontrib>Nicoletto, O</creatorcontrib><creatorcontrib>Benedetti Panici, P</creatorcontrib><creatorcontrib>Tognon, G</creatorcontrib><creatorcontrib>Lissoni, A A</creatorcontrib><creatorcontrib>Bologna, A</creatorcontrib><creatorcontrib>Tomao, F</creatorcontrib><creatorcontrib>Fossati, R</creatorcontrib><creatorcontrib>Tettamanzi, F</creatorcontrib><creatorcontrib>Rulli, E</creatorcontrib><creatorcontrib>Galli, F</creatorcontrib><creatorcontrib>Alvisi, M F</creatorcontrib><creatorcontrib>Torri, V</creatorcontrib><creatorcontrib>Biagioli, E</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colombo, N</au><au>Nicoletto, O</au><au>Benedetti Panici, P</au><au>Tognon, G</au><au>Lissoni, A A</au><au>Bologna, A</au><au>Tomao, F</au><au>Fossati, R</au><au>Tettamanzi, F</au><au>Rulli, E</au><au>Galli, F</au><au>Alvisi, M F</au><au>Torri, V</au><au>Biagioli, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer</atitle><jtitle>Annals of oncology</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>suppl_8</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdy285.209</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2018-10, Vol.29 (suppl_8)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdy285_209
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title 1002TiPBAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T17%3A52%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1002TiPBAROCCO:%20A%20randomized%20phase%20II%20study%20of%20weekly%20paclitaxel%20vs%20cediranib-olaparib%20with%20continuous%20schedule%20vs%20cediranib-olaparib%20with%20intermittent%20schedule%20in%20advanced%20platinum%20resistant%20ovarian%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Colombo,%20N&rft.date=2018-10-01&rft.volume=29&rft.issue=suppl_8&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy285.209&rft_dat=%3Coup%3E10.1093/annonc/mdy285.209%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdy285.209&rfr_iscdi=true